Trials / Completed
CompletedNCT00317915
Irbesartan in Type 2 Diabetes
The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Steno Diabetes Center Copenhagen · Academic / Other
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this multicenter, doubleblind, randomized study was to investigate the renoprotective effect of irbesartan treatment in patients with type 2 diabetes and microalbuminuria (a precursor of diabetic kidney disease). 590 patients were randomized to a median 24 months of treatment with 300 mg irbesartan once daily, 150 mg irbesartan once daily or placebo. Time to development of overt nephropathy, defined by persistent proteinuria, was the primary outcome measure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irbesartan treatment |
Timeline
- First posted
- 2006-04-25
- Last updated
- 2006-04-25
Source: ClinicalTrials.gov record NCT00317915. Inclusion in this directory is not an endorsement.